Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.2.0.727
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 30, 2015
Jun. 30, 2014
OPERATING ACTIVITIES    
Net loss $ (11,287,502) $ (6,040,808)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services $ 506,928  
Warrants issued for services   $ 1,078,669
Stock option expense $ 2,902,558 $ 1,119,724
Change in fair value of contingent consideration (3,123,766)  
Share in losses on investment in joint venture 97,949  
Depreciation 28,082 $ 11,750
Amortization of intangible assets 855,877 $ 148,969
Impairment of Intangibles 338,906  
Changes in operating assets and liabilities    
Prepaid expenses and deposits $ (379,010) $ 49,924
Other receivables and other current assets   (28,519)
Accounts payable and accrued expenses $ 1,575,997 (122,187)
Net Cash Used in Operating Activities $ (8,483,981) (3,782,478)
INVESTING ACTIVITIES    
Acquisition of SKS Ocular's assets   $ (3,500,000)
Investment in joint venture $ (100,000)  
Purchase of property and equipment (182,845)  
Net Cash Used in Investing Activities (282,845) $ (3,500,000)
FINANCING ACTIVITIES    
Proceeds for issuance of common stock for cash 26,582,998 16,876,000
Proceeds from warrants exercised for cash 80,003 260,752
Repayments of short-term notes payable (137,050) (99,134)
Net Cash Provided by Financing Activities 26,525,951 17,037,618
NET CHANGE IN CASH 17,759,125 9,755,140
CASH AT BEGINNING OF PERIOD 13,220,494 5,122,895
CASH AT END OF PERIOD 30,979,619 14,878,035
CASH PAID FOR:    
Interest $ 3,924 $ 513
Income Taxes    
NON CASH FINANCING ACTIVITIES:    
Financing of insurance premiums through issuance of short term notes $ 212,400 $ 194,000
Conversion of preferred for common stock   50
Common stock issued to acquire intangible assets   10,180,224
Common stock issued to settle accounts payable $ 50,000 $ 50,000